AVDL
Income statement / Annual
Last year (2024), Avadel Pharmaceuticals plc's total revenue was $169.12 M,
an increase of 504.79% from the previous year.
In 2024, Avadel Pharmaceuticals plc's net income was -$48.83 M.
See Avadel Pharmaceuticals plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$169.12 M |
$27.96 M |
$0.00 |
$0.00 |
$22.33 M |
$59.22 M |
$103.27 M |
$172.74 M |
$150.25 M |
$173.21 M |
| Cost of Revenue |
$15.28 M
|
$846,000.00
|
$1.49 M
|
$815,000.00
|
$5.74 M
|
$12.13 M
|
$17.52 M
|
$16.30 M
|
$13.25 M
|
$10.92 M
|
| Gross Profit |
$153.84 M
|
$27.12 M
|
-$1.49 M
|
-$815,000.00
|
$16.59 M
|
$47.09 M
|
$85.75 M
|
$156.44 M
|
$137.00 M
|
$162.29 M
|
| Gross Profit Ratio |
0.91
|
0.97
|
0
|
0
|
0.74
|
0.8
|
0.83
|
0.91
|
0.91
|
0.94
|
| Research and Development Expenses |
$15.20 M
|
$13.26 M
|
$20.70 M
|
$17.10 M
|
$20.44 M
|
$32.92 M
|
$39.33 M
|
$34.22 M
|
$34.61 M
|
$25.61 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$100.36 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$181.04 M
|
$151.71 M
|
$74.52 M
|
$68.50 M
|
$32.41 M
|
$30.18 M
|
$100.36 M
|
$58.86 M
|
$44.18 M
|
$21.71 M
|
| Other Expenses |
$0.00
|
$0.00
|
$3.35 M
|
$217,000.00
|
$406,000.00
|
$816,000.00
|
$1.90 M
|
$2.09 M
|
-$6.55 M
|
$0.00
|
| Operating Expenses |
$196.24 M
|
$164.97 M
|
$95.22 M
|
$85.60 M
|
$53.25 M
|
$63.92 M
|
$146.31 M
|
$96.74 M
|
$92.68 M
|
$59.88 M
|
| Cost And Expenses |
$211.52 M
|
$165.81 M
|
$95.22 M
|
$85.60 M
|
$59.00 M
|
$76.04 M
|
$163.82 M
|
$113.04 M
|
$105.93 M
|
$70.81 M
|
| Interest Income |
$0.00
|
$0.00
|
$11.12 M
|
$2.13 M
|
$12.59 M
|
$1.07 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$10.83 M
|
$9.89 M
|
$12.34 M
|
$9.94 M
|
$12.99 M
|
$12.48 M
|
$10.62 M
|
$1.05 M
|
$963,000.00
|
$6.30 M
|
| Depreciation & Amortization |
$2.68 M
|
$1.77 M
|
$1.49 M
|
$815,000.00
|
$1.69 M
|
$2.49 M
|
$7.43 M
|
$4.88 M
|
$14.49 M
|
$13.13 M
|
| EBITDA |
-$35.57 M |
-$149.13 M |
-$97.60 M |
-$84.78 M |
-$34.97 M |
-$23.61 M |
-$95.15 M |
$65.89 M |
$5.73 M |
$115.54 M |
| EBITDA Ratio |
-0.21
|
-5.33
|
0
|
0
|
-1.42
|
-0.24
|
-0.51
|
0.37
|
0.39
|
0.67
|
| Operating Income Ratio |
-0.25
|
-4.93
|
0
|
0
|
-1.64
|
-0.28
|
-1.02
|
0.51
|
-0.03
|
0.41
|
| Total Other Income/Expenses Net |
-$6.68 M
|
-$22.93 M
|
-$12.88 M
|
-$7.60 M
|
-$10.90 M
|
-$14.47 M
|
-$8.27 M
|
$3.16 M
|
-$4.75 M
|
$6.26 M
|
| Income Before Tax |
-$49.08 M
|
-$160.78 M
|
-$111.44 M
|
-$93.15 M
|
-$5.08 M
|
-$38.58 M
|
-$113.20 M
|
$91.47 M
|
-$9.72 M
|
$78.39 M
|
| Income Before Tax Ratio |
-0.29
|
-5.75
|
0
|
0
|
-0.23
|
-0.65
|
-1.1
|
0.53
|
-0.06
|
0.45
|
| Income Tax Expense |
-$247,000.00
|
-$501,000.00
|
$26.03 M
|
-$15.82 M
|
-$12.11 M
|
-$5.36 M
|
-$17.89 M
|
$24.22 M
|
$31.56 M
|
$37.74 M
|
| Net Income |
-$48.83 M
|
-$160.28 M
|
-$137.46 M
|
-$77.33 M
|
$7.03 M
|
-$33.23 M
|
-$95.30 M
|
$67.25 M
|
-$41.28 M
|
$40.66 M
|
| Net Income Ratio |
-0.29
|
-5.73
|
0
|
0
|
0.31
|
-0.56
|
-0.92
|
0.39
|
-0.27
|
0.23
|
| EPS |
-0.51 |
-2 |
-2.29 |
-1.32 |
0.13 |
-0.89 |
-2.55 |
1.66 |
-1 |
1 |
| EPS Diluted |
-0.51 |
-2 |
-2.29 |
-1.32 |
0.13 |
-0.89 |
-2.55 |
1.61 |
-1 |
0.93 |
| Weighted Average Shares Out |
$95.14 M
|
$80.17 M
|
$60.09 M
|
$58.54 M
|
$53.00 M
|
$37.40 M
|
$37.33 M
|
$40.47 M
|
$41.25 M
|
$40.58 M
|
| Weighted Average Shares Out Diluted |
$95.14 M
|
$80.17 M
|
$60.09 M
|
$58.54 M
|
$54.94 M
|
$37.40 M
|
$37.33 M
|
$41.77 M
|
$41.25 M
|
$43.62 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
